Analysis of cervical cancer screening results in HIV-infected women
FU Lihua1 LI Man2 YI Nuo1▲
1.Department of Obstetrics and Gynecology, Beijing Ditan Hosptal, Capital Medical University, Beijing 100015, China;
2.Department of Pathology, Beijing Ditan Hosptal, Capital Medical University, Beijing 100015, China
Abstract：Objective To analyze the screening results of cervical cancer in women infected with human immunodeficiency virus (HIV), and to provide evidence for the prevention and management of cervical lesions in women infected with HIV. Methods Cervical thinprep cytologic test (TCT) and human papilloma virus (HPV) inspection data from Department of Obstetrics and Gynecology, Beijing Ditan Hospital, Capital Medical University were selected from January 2018 to October 2020. A total of 137 HIV positive women were in study group and 2891 HIV negative women were in control group. Abnormal TCT and distribution of HPV subtypes in two groups were analyzed. Results The positive rate of high-risk HPV, low-risk HPV and multiple infection in study group were higher than those in control group. In study group, type 52, 16, 18, 53 were the most common HPV types; and in control group, type 52, 16, 58 and 18 were more common HPV types. In study group, 29 cases (21.16%) were abnormal TCT; and in control group, abnormal TCT was 220 cases (7.61%). Conclusion The cervical HPV positive detection rate of HIV positive women is higher than that of HIV negative women, and the incidence of cervical lesions is higher than that of HIV negative women. Women infected with HIV should be considered at high risk of cervical cancer and the screening time should be shortened.
付丽华1 李慢2 伊诺1▲. HIV感染女性宫颈癌筛查结果分析[J]. 中国医药导报, 2021, 18(24): 99-102.
FU Lihua1 LI Man2 YI Nuo1▲. Analysis of cervical cancer screening results in HIV-infected women. 中国医药导报, 2021, 18(24): 99-102.
[1] 中华医学会感染病学分会艾滋病丙型肝炎学组，中国疾病预防控制中心.中国艾滋病诊疗指南（2018版）[J].新发传染病电子杂志，2019，4（2）：65-84．
[2] Kojic EM，Kang M，Cespedes MS，et al. Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in HIV1-infected Woman [J]. Clin Infect Dis，2014，59（1）：127-135.
[3] Solomon D，Davey D，Kurman R，et al. The 2001 Bethesda System：terminology for reporting results of cervical cytology [J]. JAMA，2002，287（16）：2114-2119.
[4] 杨丽，王静，马彩玲.预防性HPV疫苗预防宫颈癌有效性和安全性Meta分析[J].中华肿瘤防治杂志，2015，22（9）：719-727.
[5] 楼俊晓，符孜牧.女性人类免疫缺陷病毒感染与宫颈人乳头瘤状病毒感染的相关性分析[J].中国妇幼保健，2017， 32（7）：1396-1399.
[6] Bao YP，Li N，Smith JS，et al. Human papillomavirus type distribution in woman fromAsian：a meta-analysis [J]. Int J Gyneco Cancer，2008，18（1）：71-79.
[7] Clifford GM，Goncalves MA，Franceschi S. Human papillomavirus types among women infected with HIV：a meta-analysis [J]. AIDS，2006，20（18）：2337-2344.
[8] Strickler HD，Burk RD，Fazzari M，et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women [J]. J Natl Cancer Inst，2005，97（8）：577-586.
[9] 吴菊意，校丽绒，胡泷，等.艾滋病病毒感染者和艾滋病患者合并宫颈癌与癌前病变的相关影响因素[J].实用癌症杂志，2019，34（5）：846-849.
[10] 周新刚，李慢，滕晓英，等.无症状人类免疫缺陷病毒女性携带者子宫颈人乳头瘤病毒感染状况分析[J].中国妇产科临床杂志，2017，18（4）：309-312.
[11] 张永喜，熊艳，桂希恩，等.HIV阳性妇女子宫颈感染HPV状况分析[J].中华妇产科杂志，2012，47（3）：185-190.
[12] Mbulawa ZZ，Coetzee D，Marais DJ，et a1. Genital human papillomavirus prevalence anti human papillomavirus concordance in heterosexual couples are positively associated with human immunodeficiency virus co-infection [J]. J infect Dis，2009，99（10）：1514-1524.
[13] Loy A，Mcinerney J，Pilkington L，et al. Human papillomavirus DNA and mRNA prevalence and association with cervical cytological abnormalities in the Irish HIV population [J]. Int J STD AIDS，2015，26（11）：789-795.
[14] de Sanjose S，Quint WG，Alemany L，et al. Human papillomavirus genotype attribution in invasive cervical cancer：a retrospective cross-sectional worldwide study [J]. Lancet Oncol，2010，11（11）：1048-1056.
[15] 卢洪洲.艾滋病及其相关疾病诊疗常规[M].上海:上海科学技术出版社，2009.
[16] Clifford GM，Tully S，Franceschi S. Carcinogenicity of Human apillomavirus （HPV） Types in HIV-Positive Women：A Meta-Analysis From HPV Infection to Cervical Cancer [J]. Clin Infect Dis，2017，64（9）：1228-1235.
[17] Dames DN，Ragin C，Griffith-Bowe A，et al. The prevalence of cervical cytology abnormalities and human papillomavirus in women infected with the human immunodeficiency virus [J]. Infect Agent Cancer，2009，4 Suppl 1（Suppl 1）：S8.
[18] 陈丽梅.宫颈癌筛查技术发展及最新筛查指南[J].上海医药，2018，39（1）：3-7.
[19] 茅娅男，尤志学.ASCCP2019共识指南子宫颈癌筛查结果异常管理解读[J].现代妇产科进展，2021，30（1）：58-64.
[20] 吴尊友.我国艾滋病经性传播新特征与防治面临的挑战[J].中华流行病学杂志，2018，39（6）：707-709.
[21] Ellerbrock TV，Chiasson MA，Bush TJ，et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women [J]. JAMA，2000，55（6）：1031-1037.
[22] Kreimer AR，Herrero R，Sampson JN，et al. Evidence for single-dose protection by the bivalent HPV vaccine-Review of the Costa Rica HPV vaccine trial and future research studies [J]. Vaccine，36（32 Pt A）：4774-4782.
[23] Geretti AM，Brook G，Cameron C，et al. British HIV Association Guidelines on the Use of Vaccines in HIV-Positive Adults 2015 [J]. HIV Med，2016，17 Suppl 3：s2-s81.
[24] Cubas R，van Grevenynghe J，Wills S，et al. Reversible reprogramming of circulating memory T follicular helper cell function during chronic HIV infection [J]. J Immunol，2015，195（12）：5625-5636.
[25] Lacey CJ. HPV vaccination in HIV infection [J]. Papillomavirus Res，2019，8：100174.
京公网安备 11010502046598号